Medical debt can send people into “a spiral of economic disadvantage,” including a lack of stability and security in personal life, housing and work.
The ‘payvider’ model is best suited for health systems that want to double down on value-based care.
The company says it plans to file for accelerated approval later this year.
A reduction in emergency room visits is just one of the ways teledermatology has improved patient outcomes and reduced costs, according to Elizabeth K. Jones, M.D., an associate dermatology professor at Thomas Jefferson University Hospital in Philadelphia.
COVID-19 sped up healthcare’s digital transformation. The 20-minute telehealth visit can mean less unpaid time off from work and the difference between seeking care and putting food on the table. Care-at-home programs can reduce the risks associated with hospitalization, such as hospital-acquired infections.
Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.
Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.
As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Enterprise imaging platforms would enable organizations to consistently and optimally capture, index, manage, store, distribute, view, exchange and analyze all clinical imaging and multimedia content, enhancing patients’ electronic health records.
Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is available as both a subcutaneous and intravenous induction option.
Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.
Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.
Organizations setting up hospital-at-home programs need to be aware of the associated risks and mitigation best practices.
How AI-powered technology and its data-driven insights improve payer operations and reimburse providers faster.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
Engaging with payers in collaborative arrangements is critical for achieving quality outcomes at lower cost, while ensuring financial health for providers during good times and bad.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.
Health plans need to consider regulations and keep healthcare data secure to take full advantage of its enormous potential to broaden and reshape timely, effective delivery of care.
Patients with chronic conditions like asthma, diabetes, and cardiovascular disease often require emergency attention and hospitalization due to non-adherence, resulting in higher treatment costs.
Research has linked many drugs to QT prolongation and decision support tools could alert clinicians to the risk and guide prescribing decisions to safer alternatives.
As industries across the board move towards a digital-only world, pharma companies must account for the different technologies that are transforming the R&D process.